Department of Biological Sciences, Indian Institute of Science Education and Research Mohali, Sector 81, SAS Nagar Knowledge City, PO Manauli, Mohali 140306, Punjab, India.
Institut für Virologie, Freie Universität Berlin, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany; Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, 5F, Block 1B, To Yuen Building, 31 To Yuen Street, Kowloon Tong, Hong Kong.
Microbes Infect. 2023 Jan-Feb;25(1-2):105078. doi: 10.1016/j.micinf.2022.105078. Epub 2022 Nov 23.
The unprecedented success of mRNA vaccines in managing the COVID-19 pandemic raises the prospect of applying the mRNA platform to other viral diseases of humans and domesticated animals, which may lead to more efficacious vaccines for some agents. We briefly discuss reasons why mRNA vaccines achieved such success against COVID-19 and indicate what other virus infections and disease conditions might also be ripe for control using mRNA vaccines. We also evaluate situations where mRNA could prove valuable to rebalance the status of immune responsiveness and achieve success as a therapeutic vaccine approach against infections that induce immunoinflammatory lesions.
mRNA 疫苗在应对 COVID-19 大流行方面取得了前所未有的成功，这使得人们有望将该 mRNA 平台应用于人类和家养动物的其他病毒性疾病，从而为某些病原体开发出更有效的疫苗。我们简要讨论了 mRNA 疫苗在应对 COVID-19 方面取得如此成功的原因，并指出了其他哪些病毒感染和疾病状况也可能适合使用 mRNA 疫苗进行控制。我们还评估了 mRNA 在哪些情况下可能具有重要价值，可作为一种治疗性疫苗方法来重新平衡免疫反应状态，并在诱导免疫炎症性病变的感染中取得成功。
